YAP1 and non-small cell lung carcinoma: To further explore the dependence of EM2's anti‐NSCLC effect on YAP activity, we constructed a constitutive active YAP S127A mutant plasmid (Figure 5G; Figure S6E, Supporting Information), which led to the continuous transcriptional activation of YAP.